Armistice Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Armistice Capital’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-350,000	Closed	-$1.33M	–	96
2020 Q1	$1.33M	Buy	+350,000	New	+$1.51M	0.08%	72
2019 Q1	–	Sell	-5,700,000	Closed	-$23.9M	–	96
2018 Q4	$23.9M	Sell	5,700,000 -458,000	-7%	-$2.33M	1.81%	16
2018 Q3	$38.6M	Buy	6,158,000 +3,622,000	+143%	+$27.8M	2.32%	13
2018 Q2	$20.4M	Buy	2,536,000 +136,000	+6%	+$1.04M	1.33%	30
2018 Q1	$17.9M	Buy	+2,400,000	New	+$16M	1.37%	31
2015 Q2	–	Sell	-1,148,000	Closed	-$6.87M	–	35
2015 Q1	$6.87M	Buy	+1,148,000	New	+$7.22M	3.04%	15

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Armistice Capital's PGNX Position: Q2 2020 in Review

Armistice Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 350,000 shares — an estimated $1.33M sold.

Armistice Capital first reported a position in PGNX in Q1 2015 and held it in 6 quarters. The position peaked at $38.6M in Q3 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Armistice Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Armistice Capital sold 350,000 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.33M.
Armistice Capital first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 6 quarters.
Armistice Capital's Progenics Pharmaceuticals Inc position peaked at $38.6M in Q3 2018.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Armistice Capital's 13F filing for Q2 2020, filed 14 Aug 2020.